肠促胰岛素类似物和二肽基肽酶4抑制剂对脂蛋白的影响。
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.
作者信息
Zhong Jixin, Maiseyeu Andrei, Rajagopalan Sanjay
机构信息
Division of Cardiovascular Medicine, University of Maryland School of Medicine, 20 Penn St, Baltimore, MD 21201, USA.
出版信息
Clin Lipidol. 2015;10(1):103-112. doi: 10.2217/clp.14.59.
Abstract
Elevated post-prandial lipoprotein levels are common in patients with type 2 diabetes. Post-prandial lipoprotein alterations in type 2 diabetics are widely believed to drive inflammation and are considered a major risk factor for cardiovascular disease in diabetic patients. The incretins glucagon like peptide-1 (GLP-1) and glucose insulinotropic peptide (GIP) modulate post-prandial lipoproteins through a multitude of pathways that are independent of insulin and weight loss. Evidence from both animal models and humans seems to suggest an important effect on triglyceride rich lipoproteins (Apo48 containing) with little to no effects on other lipoproteins at least in humans. Dipeptidyl peptidase-4 (DPP4) inhibitors also appear to share these effects suggesting an important role for incretins in these effects. In this review, we will summarize lipid modulating effects of incretin analogs and DPP-4 inhibitors in both animal models and human studies and provide an overview of mechanisms responsible for these effects.
摘要
餐后脂蛋白水平升高在2型糖尿病患者中很常见。2型糖尿病患者的餐后脂蛋白改变被广泛认为会引发炎症，并被视为糖尿病患者心血管疾病的主要危险因素。肠促胰岛素胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）通过多种独立于胰岛素和体重减轻的途径调节餐后脂蛋白。来自动物模型和人体的证据似乎表明，其对富含甘油三酯的脂蛋白（含载脂蛋白Apo48）有重要影响，至少在人体中对其他脂蛋白几乎没有影响。二肽基肽酶-4（DPP4）抑制剂似乎也具有这些作用，表明肠促胰岛素在这些作用中发挥重要作用。在本综述中，我们将总结肠促胰岛素类似物和DPP-4抑制剂在动物模型和人体研究中的脂质调节作用，并概述造成这些作用的机制。
相似文献
1
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.肠促胰岛素类似物和二肽基肽酶4抑制剂对脂蛋白的影响。
Clin Lipidol. 2015;10(1):103-112. doi: 10.2217/clp.14.59.
2
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.二肽基肽酶抑制剂在 2 型糖尿病中的治疗作用：对肠促胰岛素轴的控制和对餐后血糖及脂代谢的调节。
Peptides. 2018 Feb;100:158-164. doi: 10.1016/j.peptides.2017.11.023.
3
Incretin hormones: Their role in health and disease.肠降血糖素：它们在健康和疾病中的作用。
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129.
4
Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea.阻塞性睡眠呼吸暂停患者的血浆肠促胰岛素水平和二肽基肽酶-4活性
Ann Am Thorac Soc. 2016 Aug;13(8):1378-87. doi: 10.1513/AnnalsATS.201510-697OC.
5
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.通过抑制二肽基肽酶IV来保存活性肠促胰岛素激素可抑制犬餐后肠促胰岛素的分泌。
J Endocrinol. 2002 Feb;172(2):355-62. doi: 10.1677/joe.0.1720355.
6
The incretin system and its role in type 2 diabetes mellitus.肠促胰岛素系统及其在2型糖尿病中的作用。
Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. doi: 10.1016/j.mce.2008.08.012. Epub 2008 Aug 20.
7
Blood pressure-lowering effects of incretin-based diabetes therapies.基于肠促胰岛素的糖尿病治疗药物的降压作用。
Can J Diabetes. 2014 Oct;38(5):364-71. doi: 10.1016/j.jcjd.2014.05.001.
8
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.胰高血糖素样肽-1、葡萄糖依赖性胰岛素促分泌多肽和二肽基肽酶-4 抑制剂在实验动物中的抗动脉粥样硬化和抗炎作用。
J Diabetes Investig. 2016 Apr;7 Suppl 1(Suppl 1):80-6. doi: 10.1111/jdi.12446. Epub 2016 Mar 31.
9
The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.肥胖与糖尿病中的肠促胰岛素系统基础知识——减肥及其他方面的新型治疗策略
Obes Rev. 2016 Jul;17(7):553-72. doi: 10.1111/obr.12421. Epub 2016 Apr 29.
10
Incretins and Lipid Metabolism.肠降血糖素与脂代谢。
Curr Med Chem. 2018;25(18):2133-2139. doi: 10.2174/0929867324666170414164244.
引用本文的文献
1
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.代谢性疾病口腔生物大分子疗法的进展
Pharmaceutics. 2025 Feb 12;17(2):238. doi: 10.3390/pharmaceutics17020238.
2
Effect of Sitagliptin Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial.西他列汀与格列本脲对2型糖尿病患者血糖指标、血脂谱、炎症及氧化应激因子的影响：一项双盲随机对照试验
Maedica (Bucur). 2022 Dec;17(4):762-770. doi: 10.26574/maedica.2022.17.4.762.
3
Persistence of Lipoproteins and Cholesterol Alterations after Sepsis: Implication for Atherosclerosis Progression.脓毒症后脂蛋白和胆固醇改变的持续存在：对动脉粥样硬化进展的影响。
Int J Mol Sci. 2021 Sep 29;22(19):10517. doi: 10.3390/ijms221910517.
4
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.利拉鲁肽治疗可改善血糖控制良好的 2 型糖尿病患者的餐后脂质代谢和心血管代谢危险因素：一项单中心随机对照研究。
Diabetes Obes Metab. 2019 Jan;21(1):84-94. doi: 10.1111/dom.13487. Epub 2018 Sep 4.
5
The regulatory role of DPP4 in atherosclerotic disease.二肽基肽酶4（DPP4）在动脉粥样硬化疾病中的调节作用。
Cardiovasc Diabetol. 2017 Jun 15;16(1):76. doi: 10.1186/s12933-017-0558-y.
6
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.二肽基肽酶-4抑制剂的心血管效应
Hippokratia. 2015 Jul-Sep;19(3):195-9.
7
Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.基于肠促胰岛素的糖尿病治疗：心脏病专家需要了解的内容。
J Am Coll Cardiol. 2016 Mar 29;67(12):1488-1496. doi: 10.1016/j.jacc.2015.12.058.
8
GLP-1 Agonists and Blood Pressure: A Review of the Evidence.GLP-1 激动剂与血压：证据回顾。
Curr Hypertens Rep. 2016 Feb;18(2):16. doi: 10.1007/s11906-015-0621-6.
9
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.二肽基肽酶-4抑制疗法的最新进展：来自实验室研究和临床试验的经验教训
J Diabetes Res. 2015;2015:606031. doi: 10.1155/2015/606031. Epub 2015 May 14.
10
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.二肽基肽酶4在心脏代谢疾病中的作用：二肽基肽酶4抑制的实验室研究和临床试验的最新见解
Circ Res. 2015 Apr 10;116(8):1491-504. doi: 10.1161/CIRCRESAHA.116.305665.
本文引用的文献
1
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.GLP-1 受体激活调节人类的食欲和奖励相关脑区。
Diabetes. 2014 Dec;63(12):4186-96. doi: 10.2337/db14-0849. Epub 2014 Jul 28.
2
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.1980 至 2013 年期间全球、地区和国家儿童和成人超重和肥胖患病率：2013 年全球疾病负担研究的系统分析。
Lancet. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29.
3
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.神经元 GLP1R 介导利拉鲁肽的厌食作用，但不介导其降血糖作用。
J Clin Invest. 2014 Jun;124(6):2456-63. doi: 10.1172/JCI72434. Epub 2014 Apr 24.
4
Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.西他列汀，一种 DPP-4 抑制剂，可在健康人群中急性抑制肠道脂蛋白颗粒分泌。
Diabetes. 2014 Jul;63(7):2394-401. doi: 10.2337/db13-1654. Epub 2014 Feb 28.
5
New and emerging regulators of intestinal lipoprotein secretion.肠道脂蛋白分泌的新的和新兴调节因子。
Atherosclerosis. 2014 Apr;233(2):608-615. doi: 10.1016/j.atherosclerosis.2013.12.047. Epub 2014 Jan 21.
6
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.单分子双重肠降血糖素可使啮齿动物、猴子和人类的代谢获益最大化。
Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.
7
Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6.胰高血糖素样肽 1 受体抑制食欲和体重的作用是通过中枢白细胞介素 1 和白细胞介素 6 介导的。
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16199-204. doi: 10.1073/pnas.1306799110. Epub 2013 Sep 18.
8
Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.升高的残余胆固醇既引起低度炎症又引起缺血性心脏病，而升高的低密度脂蛋白胆固醇引起缺血性心脏病而无炎症。
Circulation. 2013 Sep 17;128(12):1298-309. doi: 10.1161/CIRCULATIONAHA.113.003008. Epub 2013 Aug 7.
9
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.阿格列汀可改善非糖尿病患者的餐后血脂异常和餐后内皮功能障碍：初步报告。
Cardiovasc Diabetol. 2013 Jan 9;12:8. doi: 10.1186/1475-2840-12-8.
10
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.GLP-1 受体激动剂可间接减少肝脏脂质蓄积，但不能减轻糖尿病雄性 ApoE(-/-)小鼠动脉粥样硬化的发生。
Endocrinology. 2013 Jan;154(1):127-39. doi: 10.1210/en.2012-1937. Epub 2012 Nov 26.
Zotero 插件